2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee.

[1]  T. Villines,et al.  Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. , 2019, Annals of emergency medicine.

[2]  T. Maddox,et al.  2019 Methodology for Creating Expert Consensus Decision Pathways: A Report of the American College of Cardiology. , 2019, Journal of the American College of Cardiology.

[3]  Ashutosh Kumar Singh,et al.  Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial , 2019, Lancet.

[4]  M. Crowther,et al.  Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum , 2019, American journal of hematology.

[5]  J. Dogné,et al.  Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma , 2019, International journal of laboratory hematology.

[6]  D. Witt,et al.  Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis. , 2019, Thrombosis research.

[7]  A. Demchuk,et al.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors , 2019, The New England journal of medicine.

[8]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.

[9]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.

[10]  H. Schünemann,et al.  Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. , 2019, Blood advances.

[11]  B. Ritchie,et al.  Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study , 2018, Thrombosis and Haemostasis.

[12]  Young-A. Heo.  Andexanet Alfa: First Global Approval , 2018, Drugs.

[13]  B. Ritchie,et al.  Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study , 2018, Thrombosis and Haemostasis.

[14]  J. Dogné,et al.  Betrixaban: Impact on Routine and Specific Coagulation Assays—A Practical Laboratory Guide , 2018, Thrombosis and Haemostasis.

[15]  Jamie N. Brown,et al.  Characterizing the Severe Reactions of Parenteral Vitamin K1 , 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[16]  K. Mahaffey,et al.  2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. , 2017, Journal of the American College of Cardiology.

[17]  J. Odeberg,et al.  Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. , 2017, Blood.

[18]  L. See,et al.  Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation , 2017, JAMA.

[19]  T. Steiner,et al.  Idarucizumab for Dabigatran Reversal — Full Cohort Analysis , 2017, The New England journal of medicine.

[20]  L. Fleisher,et al.  2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[21]  F. Skjøth,et al.  Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation , 2017, JAMA internal medicine.

[22]  D. Adams.  Idarucizumab for Dabigatran Reversal Full Cohort Analysis , 2017 .

[23]  T. Ortel,et al.  2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. , 2017, Journal of the American College of Cardiology.

[24]  Y. Zhang,et al.  Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation , 2017, Stroke.

[25]  M. Bottai,et al.  Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding , 2016, Thrombosis and Haemostasis.

[26]  M. Mercuri,et al.  Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban , 2016, Thrombosis and Haemostasis.

[27]  A. Camm,et al.  Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary , 2016, European heart journal.

[28]  D. Siegal,et al.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review , 2017, Chest.

[29]  H. Kamel,et al.  Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis , 2017, Stroke.

[30]  S. Connolly,et al.  Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa , 2016 .

[31]  Sunil V. Rao,et al.  Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. , 2016, JAMA.

[32]  G. Lip,et al.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.

[33]  Mauricio G. Cohen,et al.  The association between in-hospital hemoglobin changes, cardiovascular events, and mortality in acute decompensated heart failure: Results from the ESCAPE trial. , 2016, International journal of cardiology.

[34]  N. Heddle,et al.  Red blood cell transfusion: 2016 clinical practice guidelines from AABB , 2016, Transfusion.

[35]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[36]  S. Connolly,et al.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. , 2016, The New England journal of medicine.

[37]  T. Milling,et al.  Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed,, , 2016, The American journal of medicine.

[38]  A. Iorio,et al.  Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis , 2016, Thrombosis and Haemostasis.

[39]  M. S. Mcmurtry,et al.  Secular Trends in Incidence and Mortality of Acute Venous Thromboembolism: The AB-VTE Population-Based Study. , 2016, The American journal of medicine.

[40]  E. Antman,et al.  Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents , 2016, Circulation.

[41]  Rustam Al-Shahi Salman,et al.  Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial , 2016, The Lancet.

[42]  A. Shenker,et al.  Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban , 2016, Journal of clinical pharmacology.

[43]  William Smith,et al.  Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis , 2016, American Journal of Nephrology.

[44]  J. Goldstein,et al.  Safety of a Four‐factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials , 2016, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[45]  M. Radford,et al.  Association Between Anemia, Bleeding, and Transfusion with Long-term Mortality Following Noncardiac Surgery. , 2016, The American journal of medicine.

[46]  G. Caleb Alexander,et al.  Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation , 2016, Journal of the American Heart Association.

[47]  Mark D. Huffman,et al.  Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.

[48]  J. Dogné,et al.  Edoxaban: Impact on routine and specific coagulation assays , 2015, Thrombosis and Haemostasis.

[49]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[50]  E. Manno,et al.  The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage , 2016, Neurocritical Care.

[51]  A. Cuker.  Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication , 2016, Journal of Thrombosis and Thrombolysis.

[52]  D. Siegal,et al.  Monitoring and reversal of direct oral anticoagulants. , 2015, Hematology. American Society of Hematology. Education Program.

[53]  Z. Goldberger,et al.  National Trends in Ambulatory Oral Anticoagulant Use. , 2015, The American journal of medicine.

[54]  R. Bellomo,et al.  Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial. , 2015, JAMA.

[55]  V. Hasselblad,et al.  Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. , 2015, The New England journal of medicine.

[56]  S. Glund,et al.  Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial , 2015, The Lancet.

[57]  G. Lip,et al.  Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study , 2015, Circulation.

[58]  T. Steiner,et al.  Idarucizumab for Dabigatran Reversal. , 2015, The New England journal of medicine.

[59]  Bcps,et al.  Idarucizumab for dabigatran reversal , 2015 .

[60]  C. Anderson,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.

[61]  T. Steiner,et al.  Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran , 2015, Thrombosis and Haemostasis.

[62]  F. Barral,et al.  Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. , 2015, JAMA.

[63]  T. Lindahl,et al.  More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. , 2015, Thrombosis research.

[64]  G. Fink,et al.  Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. , 2015, JAMA.

[65]  H. Husseinzadeh,et al.  Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review , 2015, Journal of Thrombosis and Thrombolysis.

[66]  David B Hoyt,et al.  Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. , 2015, JAMA.

[67]  D. Monroe,et al.  Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate , 2015, Anesthesiology.

[68]  E. Tapper,et al.  The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal Bleeding: A Prospective Study , 2015, The American Journal of Gastroenterology.

[69]  T. Marbury,et al.  Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis , 2015, Thrombosis and Haemostasis.

[70]  E. Antman,et al.  Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate , 2015, Circulation.

[71]  J. gardner-Gray,et al.  Delayed intracranial hemorrhage in the anticoagulated patient: A systematic review , 2013, The journal of trauma and acute care surgery.

[72]  S. Connolly,et al.  A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors , 2014 .

[73]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[74]  J. Ansell,et al.  Use of PER977 to reverse the anticoagulant effect of edoxaban. , 2014, The New England journal of medicine.

[75]  S. Caldwell,et al.  Procoagulant therapeutics in liver disease: a critique and clinical rationale , 2014, Nature Reviews Gastroenterology and Hepatology.

[76]  D. Siegal,et al.  Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. , 2014, Journal of the American College of Cardiology.

[77]  R. Goldberg,et al.  Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). , 2014, The American journal of medicine.

[78]  Manesh R. Patel,et al.  Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers , 2014, Journal of thrombosis and haemostasis : JTH.

[79]  R. Porte,et al.  Hemostasis in liver disease: implications of new concepts for perioperative management. , 2014, Transfusion medicine reviews.

[80]  D. Bakker,et al.  Low risk of late intracranial complications in mild traumatic brain injury patients using oral anticoagulation after an initial normal brain computed tomography scan: education instead of hospitalization , 2014, European journal of neurology.

[81]  D. Keeling,et al.  Activated prothrombin complex concentrate for the prevention of dabigatran‐ associated bleeding , 2014, British journal of haematology.

[82]  M. Dittrich,et al.  Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests , 2014, Clinical chemistry and laboratory medicine.

[83]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[84]  Zaid Alirhayim,et al.  Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. , 2014, The American journal of cardiology.

[85]  B. Ritchie,et al.  Activated prothrombin complex concentrate for dabigatran‐associated bleeding , 2014, British journal of haematology.

[86]  W. Ageno,et al.  Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. , 2013, Thrombosis research.

[87]  J. Goldstein,et al.  Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma-Controlled, Phase IIIb Study , 2013, Circulation.

[88]  E. Nutescu.  Oral anticoagulant therapies: balancing the risks. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[89]  M. Chintala,et al.  Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[90]  M. Poca,et al.  Transfusion strategies for acute upper gastrointestinal bleeding. , 2013, The New England journal of medicine.

[91]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[92]  C. Konrad,et al.  Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™ , 2012, Der Anaesthesist.

[93]  E. Herzog,et al.  Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model , 2012, Journal of thrombosis and haemostasis : JTH.

[94]  A. Barkun,et al.  Platelet Transfusion Threshold in Patients With Upper Gastrointestinal Bleeding: A Systematic Review , 2012, Journal of clinical gastroenterology.

[95]  S. Zehtabchi,et al.  Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: A systematic review , 2012, The journal of trauma and acute care surgery.

[96]  J. Cracowski,et al.  Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban , 2012, Thrombosis and Haemostasis.

[97]  A. Grayson,et al.  A meta-analysis to determine the effect on survival of platelet transfusions in patients with either spontaneous or traumatic antiplatelet medication-associated intracranial haemorrhage , 2012, BMJ Open.

[98]  Jason C. Fish,et al.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[99]  Douglas S. Lee,et al.  Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. , 2012, The Canadian journal of cardiology.

[100]  Á. Chamorro,et al.  Oral anticoagulant-associated intracerebral hemorrhage , 2012, Journal of Neurology.

[101]  A. Kirkpatrick,et al.  Clinical review: Canadian National Advisory Committee on Blood and Blood Products - Massive Transfusion Consensus Conference 2011: report of the panel , 2011, Critical care.

[102]  S. Heiland,et al.  Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran , 2011, Stroke.

[103]  P. Kamphuisen,et al.  Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.

[104]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[105]  A. Peitzman,et al.  Crystalloid resuscitation improves survival in trauma patients receiving low ratios of fresh frozen plasma to packed red blood cells. , 2011, The Journal of trauma.

[106]  Gordon H. Guyatt,et al.  Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis , 2011 .

[107]  H. Bruck,et al.  Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. , 2010, British journal of clinical pharmacology.

[108]  C. Anderson,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2010, Stroke.

[109]  A. McDonald,et al.  Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial , 2010, The Lancet.

[110]  G. Hawryluk,et al.  Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk , 2010, Journal of thrombosis and haemostasis : JTH.

[111]  K. Rathgen,et al.  Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate , 2010, Clinical pharmacokinetics.

[112]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[113]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[114]  C. Stevens,et al.  David Geffen School of Medicine at UCLA. , 2010, Academic medicine : journal of the Association of American Medical Colleges.

[115]  J. Sevransky.  Clinical assessment of hemodynamically unstable patients , 2009, Current opinion in critical care.

[116]  A. Busti,et al.  Evidence-based treatment recommendations for uremic bleeding , 2007, Nature Clinical Practice Nephrology.

[117]  Samir M Fakhry,et al.  How low is too low? Cardiac risks with anemia , 2004, Critical care.

[118]  Yuchiao Chang,et al.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.

[119]  S. Tenner,et al.  Early Intensive Resuscitation of Patients With Upper Gastrointestinal Bleeding Decreases Mortality , 2001, American Journal of Gastroenterology.

[120]  P. Alderson,et al.  Colloids versus crystalloids for fluid resuscitation in critically ill patients. , 2000, The Cochrane database of systematic reviews.

[121]  M. Contreras.  Final statement from the consensus conference on platelet transfusion , 1998, Transfusion.

[122]  F. Barral,et al.  A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. , 1998, The New England journal of medicine.

[123]  G. Remuzzi,et al.  Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. , 1983, The New England journal of medicine.

[124]  D. Deykin,et al.  Treatment of the bleeding tendency in uremia with cryoprecipitate. , 1980, The New England journal of medicine.